Korro Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRRO research report →
Range $15 – $15
Price Chart
About the company
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
- CEO
- Ram Aiyar
- IPO
- 2019
- Employees
- 57
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on KRRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $97.58M
- P/E
- -0.98
- PEG
- 0.06
- P/S
- 40.96
- P/B
- 1.67
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
- Gross Margin
- 72.75%
- Op Margin
- -3176.57%
- Net Margin
- -4477.08%
- ROE
- -114.26%
- ROIC
- -49.21%
Latest fiscal year · YoY change
- Revenue
- $6.39M+181.5%
- Gross Profit
- $2.11M-7.0%
- Op Income
- $-87,342,000
- Net Income
- $-117,260,000-40.3%
- EPS
- $-12.48-33.2%
- OCF Growth
- -30.8%
- FCF Growth
- -1.4%
- 52W High
- $55.89
- 52W Low
- $5.20
- 50D MA
- $11.92
- 200D MA
- $11.70
- Beta
- 2.25
- RSI (14)
- 37
- Avg Volume
- 151.07K
No earnings-call transcripts are available for KRRO yet.
- Free Float
- 64.7%
- Shares Outstanding
- 9.95M
- Float Shares
- 6.44M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynx1 Capital Management LP | 1.54M | 0 |
| Nea Management Company, LLC | 1.30M | 0 |
| Vr Adviser, LLC | 1.01M | 0 |
| Atlas Venture Life Science Advisors, LLC | 962.88K | ▼ 174.26K |
| Balyasny Asset Management L.P. | 951.78K | ▼ 88.27K |
| Blackrock, Inc. | 817.62K | ▲ 357.62K |
| Affinity Asset Advisors, LLC | 706.90K | 0 |
| Nantahala Capital Management, LLC | 660.04K | 0 |
| Adage Capital Partners Gp, L.L.C. | 540.97K | ▲ 312.57K |
| Adar1 Capital Management, LLC | 540.05K | 0 |
| Vanguard Group Inc | 489.64K | ▲ 93.98K |
| Vanguard Capital Management LLC | 454.78K | ▲ 143.87K |
Held by 106 ETFs
Biggest fund positions in KRRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | FORMELA JEAN FRANCOIS | sell | 8,450 |
| Sep 14, 26 | FORMELA JEAN FRANCOIS | sell | 31,888 |
| Sep 11, 26 | FORMELA JEAN FRANCOIS | sell | 1,750 |
| Sep 14, 26 | FORMELA JEAN FRANCOIS | sell | 6,602 |
| Sep 11, 26 | Dolan Oliver | sell | 5 |
| Sep 8, 26 | Dolan Oliver | sell | 7,347 |
| Sep 9, 26 | Dolan Oliver | sell | 6 |
| Aug 26, 26 | FORMELA JEAN FRANCOIS | sell | 249 |
| Aug 26, 26 | FORMELA JEAN FRANCOIS | sell | 51 |
| Aug 19, 26 | FORMELA JEAN FRANCOIS | sell | 23,584 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRRO coverage
Recent articles, reports, and earnings notes.
No research on KRRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRRO report →Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
globenewswire.com · Oct 5
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by Brokerages
defenseworld.net · Sep 21
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 11
Korro to Participate in Upcoming Investor Conferences
globenewswire.com · Aug 27
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Moderate Buy” by Analysts
defenseworld.net · Aug 27
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 14
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
zacks.com · Aug 10
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.